Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.

American journal of clinical oncology - 1 Oct 2017

Charlton Mary E, Karlitz Jordan J, Schlichting Jennifer A, Chen Vivien W, Lynch Charles F

Abstract excerpt

OBJECTIVES: Response to epidermal growth factor receptor inhibitors is poorer among stage IV colorectal cancer (CRC) patients with KRAS mutations; thus KRAS testing is recommended before treatment. KRAS testing was collected by Surveillance, Epidemiology, and End Results (SEER) registries for 2010 CRC cases, and our goal was to provide the first population-based estimates of testing in the United States. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to DNA Mutational Analysis

Share to Proto-Oncogene Proteins p21(ras)

Share to SEER Program

Share to Survival Analysis

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 25844824
DOI: 10.1097/COC.0000000000000191
PMCID: PMC4591083

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.PMID 25844824Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer.Semantic proximity Read ↗

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.Semantic proximity Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.Semantic proximity Read ↗

KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013.Semantic proximity Read ↗

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.Semantic proximity Read ↗

Racial Differences in Stage IV Colorectal Cancer Molecular Profiling and Mutation Rates.Semantic proximity Read ↗

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.Semantic proximity Read ↗

KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

Biomarker Testing Disparities in Metastatic Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.